Data presented at the 68th American Academy of Neurology 2016 Annual Meeting in Vancouver, Canada, supports the use of Lemtrada (alemtuzumab) in the treatment of relapsing-remitting multiple sclerosis (RRMS), pharma Sanofi Genzyme has announced.
The data, taken from the on-going, long-term extension study of the phase 2 CAMMS223 study showed that over 10 years of follow-up, 76% of patients were shown to be free from 6-month confirmed disability worsening and 78% had an Expanded Disability Status Scale [EDSS] score that was either stable or showed greater than or equal to one point improvement in EDSS vs baseline.
Additionally, a low annualised relapse rate was maintained over the period, while the long-term safety observed in this group of patients was in line with that of other alemtuzumab clinical trials.
People who entered the CAMMS223 study had not previously received other treatments for RRMS and the majority of those who were followed for 10 years received a maximum of three courses of alemtuzumab.
“These data provide further evidence of the long-term response with Lemtrada in treatment-naïve patients with relapsing-remitting MS,” said Professor Alasdair Coles, Lead Investigator, University of Cambridge School of Clinical Medicine. “It is remarkable that such infrequent dosing with Lemtrada offers stability or improvement of disability over 10 years. These findings confirm that Lemtrada is a valid treatment approach for people with multiple sclerosis, without the need for continuous treatment.”
Peter Kuiper, General Manager UK & Ireland at Sanofi Genzyme, added: “We are very pleased with these new data, which are part of our extensive clinical development programme and our commitment to the field of MS. Being able to offer this treatment option, which was discovered and developed in the UK to clinicians and their patients is of incredible importance to us.”
More than 100,000 people in the UK have multiple sclerosis, with around 85% diagnosed with RRMS. Lemtrada is the second of Sanofi Genzyme’s treatments for MS to receive approval for use from NICE and on the NHS in England and Wales.